AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan

Rhea-AI Filing Summary

AstraZeneca PLC officer Mani Sharma acquired 1 Ordinary Share as a compensation grant under the company’s Share Incentive Plan. The award was valued at $179.75 per share, based on a GBP134.54 price converted at a GBP1.0000 to $1.3360 rate. Following this grant, Sharma directly holds 19,263.4659 AstraZeneca Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sharma Mani

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	1	$179.75	$179.75

Holdings After Transaction: Ordinary Shares — 19,263.466 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 1 Ordinary Share Grant valuation price: $179.75 per share Holdings after transaction: 19,263.4659 shares +2 more

5 metrics

Shares granted 1 Ordinary Share Grant under Share Incentive Plan on June 8, 2026

Grant valuation price $179.75 per share Converted from GBP134.54 for the share award

Holdings after transaction 19,263.4659 shares Direct ownership following the grant

GBP share price GBP134.54 per share Basis for conversion to U.S. dollars

FX conversion rate GBP1.0000 = $1.3360 Rate used on June 5, 2026

Key Terms

Share Incentive Plan, Grant, award, or other acquisition, Ordinary Shares, conversion rate

4 terms

Share Incentive Plan financial

"Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP134.54"

A share incentive plan is a company program that gives employees or directors the chance to receive or buy company shares, often after staying with the firm or meeting performance goals. It matters to investors because it’s like giving workers a slice of the company pie to boost performance and loyalty, but issuing those slices can reduce each existing owner’s portion and change metrics such as earnings per share and share count.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

conversion rate financial

"converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3360"

Conversion rate is the proportion of items, people or contracts that take a desired action out of the total possible — for example the share of website visitors who make a purchase, or the number of convertible bonds that are exchanged for shares. Investors care because it measures how effectively a business or financial instrument turns opportunity into real outcomes, like sales or share issuance, which directly affects revenue, cash flow and ownership dilution.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharma Mani

(Last) (First) (Middle)

C/O ASTRAZENECA PLC 1 FRANCIS

CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE CB2 0AA

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/08/2026		A		1	A	$179.75(1)	19,263.4659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP134.54, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3360 on June 5, 2026 as published by the Board of Governors of the Federal Reserve System.

Remarks:

SVP, Group Controller and Head of Global Finance Services

	/s/ Mani Sharma	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AstraZeneca (AZN) report for Mani Sharma?

AstraZeneca reported that officer Mani Sharma received 1 Ordinary Share as a share-based compensation grant under the company’s Share Incentive Plan, increasing direct holdings to 19,263.4659 shares after the transaction.

Was Mani Sharma’s AstraZeneca share transaction a market purchase or a grant?

The transaction was a share grant, not a market purchase. Sharma acquired 1 Ordinary Share classified as a “Grant, award, or other acquisition” under the company’s Share Incentive Plan, rather than buying shares on the open market.

At what price was Mani Sharma’s AstraZeneca share grant valued?

The 1 Ordinary Share granted to Mani Sharma was valued at $179.75 per share. This value reflects a GBP134.54 share price converted into U.S. dollars using a GBP1.0000 to $1.3360 exchange rate on June 5, 2026.

How many AstraZeneca shares does Mani Sharma hold after this Form 4 transaction?

After the reported grant, Mani Sharma directly holds 19,263.4659 AstraZeneca Ordinary Shares. This total includes the newly awarded 1 share and represents the direct ownership position reported in the Form 4 filing.

What is the role of AstraZeneca’s Share Incentive Plan in this Form 4 filing?

The Share Incentive Plan is the program through which the reported 1-share award was made to Mani Sharma. It provides share-based compensation, with this grant disclosed as a “Grant, award, or other acquisition” rather than a cash-based payment.